OVX-836 is under clinical development by Osivax and currently in Phase II for Unspecified Influenza Virus Infections. According to GlobalData, Phase II drugs for Unspecified Influenza Virus Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OVX-836 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OVX-836 overview
OVX-836 (IMX-836) was under development for the prevention of seasonal influenza virus infections, influenza A virus, H1N1 subtype infections and influenza A virus, H5N1 subtype infections. The vaccine candidate is based on oligoDOM (IMX313) technology. It is formulated as a solution and administered through intramuscular or intranasal route. IMX313 is a short DNA sequence fused to the antigen gene. It was also under development for pandemic influenza infections. It acts by targeting nucleoprotein.
Osivax overview
Osivax is a clinical-stage biotechnology company that develops vaccines and immunotherapies for infectious and immune system-associated diseases. It offers oligoDOM, a novel proprietary nanoparticles technology designed to trigger superior T-cell responses. The company’s pipeline products include OVX836 which targets the nucleoprotein (NP), a highly conserved internal antigen; OVX033 that targets corona virus nucleocapsid, an internal and invariant antigen. Its other pipeline products comprise Flunivax (A and B strains) for respiratory viruses and HPVAX for human papillomavirus (HPV). The company operates its facilities and research and development center in Australia, France and Belgium. Osivax is headquartered in Paris, Ile-de-France, France.
For a complete picture of OVX-836’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
